Journal
SCIENCE
Volume 352, Issue 6285, Pages 586-589Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.aad8852
Keywords
-
Categories
Funding
- European Union [600375]
- VIDI grant [016146327]
- CVON grant (IN-CONTROL)
- European Research Council [268985, 250172]
- Academy of Finland [141140, 2718324]
- Netherlands Organization for Scientific Research [024.002.002]
- Metagenomics in Cardiometabolic Diseases project [FP7-HEALTH-2012-INNOVATION-I-305312]
- International Human Microbiome Standards project [HEALTH-F4-2010-261376]
- Australian Postgraduate Award
- EMBL Australia International Ph.D. Fellowship
- AstraZeneca plc
- Danone
- Eli Lilly and Company
- European Research Council (ERC) [268985] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
Fecal microbiota transplantation (FMT) has shown efficacy in treating recurrent Clostridium difficile infection and is increasingly being applied to other gastrointestinal disorders, yet the fate of native and introduced microbial strains remains largely unknown. To quantify the extent of donor microbiota colonization, we monitored strain populations in fecal samples from a recent FMT study on metabolic syndrome patients using single-nucleotide variants in metagenomes. We found extensive coexistence of donor and recipient strains, persisting 3 months after treatment. Colonization success was greater for conspecific strains than for new species, the latter falling within fluctuation levels observed in healthy individuals over a similar time frame. Furthermore, same-donor recipients displayed varying degrees of microbiota transfer, indicating individual patterns of microbiome resistance and donor-recipient compatibilities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available